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FÓRMULAS DE INMUNONUTRICIÓN ENTERAL
EN LA CIRUGÍA DEL CÁNCER DE CABEZA 
Y CUELLO; UNA REVISIÓN SISTEMÁTICA
Resumen
Introducción: Un alto porcentaje de pacientes con cán-
cer de cabeza y cuello presentan un importante grado de
malnutrición. Esta malnutrición está asociada defectos de
la función inmune. Tanto la malnutrición como la inmu-
nosupresión hacen a estos pacientes susceptibles de pade-
cer complicaciones infecciosas en el postoperatorio. 
Objetivos: Algunos trabajos de pacientes que han reci-
bido inmunonutrición en el postoperatorio de cirugía por
cáncer de cabeza y cuello han mostrado un efecto benefi-
cioso en la evolución clínica y el estado inmune. Los auto-
res han llevado a cabo una revisión sistemática de los
ensayos clínicos realizados hasta la fecha, para determi-
nar el papel que tiene la inmunonutrición enteral posto-
peratoria en el tratamiento del cáncer de cabeza y cuello.
Métodos: Se identificaron 14 trabajos en los que se
habían utilizado fórmulas de inmunonutrición. Dos tra-
bajos compararon dos tipos de inmunonutrición. Resul-
tados: En algunos trabajos se observó una disminución en
los días de estancia hospitalaria, aunque la razón para
ello no está clara. Algunos estudios mostraron diferencias
significativas con menos complicaciones en los grupos que
recibieron nutriciones enriquecidas, presentando una
disminución significativa en el número de fístulas en
pacientes tratados con nutriciones con altas dosis de argi-
nina, si se compara con una nutrición con una dosis media
de arginina. 
Conclusión: Los futuros trabajos presentan retos. Es
necesario un ensayo clínico extenso, para poder realizar
recomendaciones firmes sobre el uso de la inmunonutri-
ción en el postoperatorio de pacientes intervenidos de
cáncer de cabeza y cuello.
(Nutr Hosp. 2012;27:681-690)
DOI:10.3305/nh.2012.27.3.5773
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Abstract
Introduction: Significant malnutrition exists in a high
percentage of patients with head and neck cancer. Malnu-
trition is associated with defects in immune function that
may impair the host response to malignancy. Malnutri-
tion and immunosupression make patients highly suscep-
tible to postoperative infections and complications.
Objectives: Some studies of patients receiving immuno-
nutrition in the perioperative period in head and neck
cancer have shown beneficial effects on clinical outcome
and inmune status. The authors carried out a systematic
review of randomised control trials to determine whether
perioperative immunonutrition has a role in the treat-
ment of head and neck cancer. 
Methods: 14 trials of polymeric nutritional supplemen-
tation with immunonutrition were identified. Two studies
compared two types of immunonutrition. 
Results: A reduction in the length of postoperative
hospital stay was seen in some trials, but the reason for
this reduction is not clear. Some studides showed statis-
tical differences with less complications in arginine-
enhanced group and also showed a significant decrease of
fistula complications in patients treated with a high argi-
nine dose enhanced formula, if compared with a medium
dose of arginine. 
Conclussion: Those planning future studies face
challenges. A suitable powered clinical trial is required
before firm recommendations can be made on the use of
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Introduction
Significant malnutrition exists up to 35-50% of
patients with cancer of the head and neck1. Many
factors contribute to malnutrition in this patient popu-
lation, including poor dietary practices, alcoholism,
catabolic factors secreted by the tumor, such the cyto-
kines tumor necrosis factor-α (TNF-α), interleukins
(IL), and gamma-interferon, local tumor effects,
anorexia, cancer-induced cachexia, and treatment
effects2. Patients undergoing surgery because of a head
and neck malignancy have a 20-50% incidence of
postoperative complications3. These complications
include major wound infections, fistula, anastomotic
leakage, respiratory insufficiency, and septicaemia and
may lead to not only a prolonged hospital stay but also
a poorer prognosis. Several factors may contribute to
this morbidity, one of which is malnutrition4.
Malnutrition is associated with defects in immune
function that may impair the host response to malig-
nancy5. The alterations in the host defence mechanism
make patients highly susceptible to postoperative
infections. Multiple components of the diet may affect
immune function. There is evidence that giving
patients perioperative nutritional supplements with
immunonutritional additives can favourably modulate
the immune and inflammatory response both in vitro
and in patients with trauma, burns or those undergoing
oncological surgery6. In particular, the important role
of amino acids, dietary nucleotides, and lipids in modu-
lating immune function has been recognized7. Arginine
is a semi-essential amino acid and the store can become
depleted in times of stress. It plays an important role in
T- and B-cell immunity as well as in the production of
nitric oxide. Arginine is able to reduce the production
of inflammatory mediators such as IL-1 beta, IL-6, and
TNF-α at the site of injury in rat septic models8 and can
accelerate tissue growth after trauma or infection9.
Dietary supplementation with arginine has positive
effects on immune function and reparative collagen
synthesis10. Nucleotides are the building blocks of
DNA and RNA and are derived from RNA in the diet.
Nucleotide restriction is associated with a significant
increase in mortality in a murine model of Candida
sepsis11. RNA supplementation is essential for the
proliferation of immune cells or cells involved in
wound healing and greatly increases the survival rate
of infected animals12. Dietary nucleotides, particularly
the pyrimidine uracil, also appear to be essential to the
normal lymphocytes maturation. Diets high in n-6
polyunsaturated fatty acids (PUFA) such as linoleic
acid are associated with the production of arachidonic
acid metabolites (prostaglandin E2 and leukotriene B4)
with adverse effects on immune function13. Diets high
in n-3 PUFA derived from fish oils, however, result in
the substitution of prostaglandins of the dienoic series
(PGE2) by prostaglandins of the trienoic series, with
different biological activities and physiological
effects14.
Omega-3 fatty acids are long-chain polyunsaturated
acids that appear to have anti-inflammatory effects,
possibly by interference with macrophage eicosanoid
production15. They play a role on the structural and
functional integrity of the cell membrane, intercellular
signal transduction, and synthesis of eicosanoids. In
particular, they influence the production of prostanoids
from the dienoic to the trienoic variety, the later of
which are much less immunosuppressive16. By repla-
cing other fatty acids with omega 3 fatty acids,
membrane flexibility is enhanced, which is essential
for phagocytes17. Decrease of proinflamatory cyto-
kines, such as Il-1β, IL-6, IL-8, and TNF-α has been
found in patients with sepsis18.
Objectives
It is reported that cancer patients receiving immuno-
nutrition perioperatively tended to have fewer postope-
rative complications19.
Some studies of patients receiving immunonutrition
in the perioperative period in head and neck cancer
have shown beneficial effects on clinical outcome and
inmune status. The authors carried out a systematic
review of randomised control trials to determine
whether perioperative immunonutrition has a role in
the treatment of head and neck cancer.
Methods
Eligibility criteria and literature search
Clinical trials were eligible if patients undergoing
head and neck surgery for cancer had been randomly
allocated to be in a control group receiving either tradi-
tional care (i.v. fluids) or polymeric nutritional supple-
ments and an interventional group receiving polymeric
nutritional supplements with immunonutritional addi-
tives. The MeSH terms used were: head and neck
neoplasms, enteral nutrition, immune, arginine, immu-
nonutrition, surgery. Papers were identified by compu-
terised searches of PubMed.
Data extraction and outcomes
Data were collected on age, sex, weight, body mass
index, energy intake, duration of supplementation, the
type of surgery, The outcomes recorded included
biochemical changes, immunological changes, wound
infections, fistula formation, mortality, and length of
postoperative hospital stay.
Results
Through data base searches, 2,017 references were
identified. After applying limits of humans and clinical
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trial 232 were retrieved, after exclusion of duplicates
and irrelevant references, 14 were retrieved. The
remaining references described 14 trials that fulfilled
the inclusion criteria and could provide data for review.
Characteristics of trials, patients and interventions
Fourteen randomised controlled trials published
between 1999 and 2010 were identified with a total of
836 patients all undergoing surgery for head and neck
cancer (tables I and 2)20-34. Twelve trials compared
polymeric feeds with immunonutrition20-21,23-33 and two
trials compared two types of immunonutrition started
at hospital discharge22,34.
Patient characteristics
Table III illustrates baseline patient characteristics.
All studies used isocaloric and isonitrogenous feed
regimens.
Wound infection and fistula formation
The effects of immunonutrition on wound infections
and fistula formation are detailed in table IV. Occu-
rrence of wound infection was reported in five trials.
The risk of wound infection ranged from 0% (0/45) to
4.8% (4/82) in immunonutrition fed groups and from
0% (0/45) to 12.5% (3/24) in control groups. The
effects of immunonutrition in malnourished patients
could only be ascertained from the study by RISO et
al.27, where 13 patients were considered malnourished.
These patients had reduced wound infections when
given immunonutrition (p < 0.05).
Occurrence of fistula formation was reported in nine
trials and ranged from 0% (0/23) to 5% (4/82) in immu-
nonutrition fed groups and from 0% (0/38) to 18.9%
(7/37) in control groups. 
Hospital stay
Mean postoperative hospital stays were long (table
IV) with broad standard deviations. De Luis et al.23
reported a significant (p < 0.05) reduction in postopera-
tive stay, 25.8 days versus 35 days in intervention and
control groups, respectively. RISO et al.27 reported a
reduced hospital stay in the intervention group (p <
0.05). 
Immunological parameters
The trials examined reported on a broad range of
biochemical and immunological parameters including
interleukin-6, tumour necrosis factor-a, C-reactive
protein, T-cell subsets and total lymphocyte counts.
Riso et al.27 demonstrated an increase in total lymp-
hocytes, CD4 and CD4/CD8 ratio on postoperative day
4 (p < 0.05).
Malnourished patients (n = 13) in the study by Riso
et al.27 showed reduced preoperative immune status in
some variables (CD4, CD4/CD8, IgA, IgG), with some
parameters (CD4, CD4/CD8) increasing postopera-
tivly compared with baseline but not between the two
groups.
Casas-Rodera et al.31 showed no significant inter-
group differences in the trend of the two plasma
proteins, lymphocytes and weight. In the three groups
that were compared there was a significant decrease of
the transferrrin at the seventh postoperative day, in
relation to preoperative levels, with a significant
increase only in the enriched diet groups, at the fourte-
enth postoperative day. The control group showed the
lower levels of lymphocytes at the seventh and fourte-
enth postoperative day. The control group showed the
highest levels of TNFα at the fourteenth postoperative
day.
Long-term survival and locoregional recurrence
Buijs et al.32 showed that the median overall long-
term survival was 34.8 months in the arginine-supple-
mented group and 20.7 months in the control group (P
= 0.019). Disease-specific survival was 94.4 months in
the arginine-supplemented group and 20.8 months in
the control group (P = 0.022). Locoregional recurrence
occurred in 4 of the 17 patients in the arginine group
and in 9 of the 15 patients in the control group.
Discussion
The authors examined 14 trials that investigated the
effects of immunonutrition in patients treated surgi-
cally for head and neck cancer. Where stated, all the
studies looking at in-hospital postoperative nutrition
used arginine as an immunonutrient, including a trial
that studies the benefits of a high dose of arginine as a
postoperative nutrition of head and neck cancer
patients34. 
A reduction in the length of postoperative hospital
stay was seen in some trials, but the reason for this
reduction is not clear. Lenght of hospital stay was
reduced in six studies. Overall reduction in these
studies conrresponded to about a 3.5 day, which is
clinically and economically important. In two studies,
fistula formation was more common in those patients
receiving immunonutrition, yet length of hospital stay
was reduced27-28.
Regarding the local complications, occurrence of
fistula formation was reported in nine trials; in 5
trials20,23,25,33,34 decrease in fistula rate was detected and
no effect was detected in 4 trials21,27,28,31. Luis et al.
Immunoenhanced enteral nutrition
formulas in head an neck cancer
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showed statistical differences with less complications
in arginine-enhanced group20,23,25, and also showed a
significant decrease of fistula complications in patients
treated with the high arginine dose enhanced formula,
if compared with a médium dose of arginine34. In this
study, length of stay was similar in both groups, the
presence of arginine in both groups could explain this
fact. Perhaps, these differences in the literature could
be explain by the diffent doses of arginine used.
Snyderman et al.28 demonstrated that a perioperative
nutritional supplementation with an immune-enhan-
cing formula was superior to standard formula in the
prevention of postoperative infectious complications.
There was no significant difference in wound healing
problems or duration of hospitalization.
Riso et al.27 confirmed that an enteral diet supple-
mented with arginine in the early postoperative period
improved postoperative immunological status and
speed up recovery from the imunodepression follo-
wing surgical trauma. On malnourished patients of this
study, administration of an enriched formula reduced
major postoperative complications and length of posto-
perative stay significantly.
Felekis et al.33, showed that the rate of complications
was significantly reduced in the total number of
patients receiving immunonutrition and in the parti-
cular subgroup of well-nourished patients receiving an
immunoenhanced diet. 
Buijs et al.32 showed that a nutritional intervention
with arginine –enriched nutrition before and after
surgery may improve survival.
Casas-Rodera et al.31 compare two immunoenhanced
enteral nutritions with a control diet, and they found
that the only general infection appeared in the control
group. Wound infections tended to be also less
frequent in the groups with enriched diets. Snyderman
et al.28 said that it was interesting to note that the incre-
ased number of infectious complications that were
observed in the control group (standard formulas) was
mostly due to infections at distant sites (lungs, urinary
tract, etc.) rather than operative wound infections. This
finding implies that most operative wound infections
and fistulas have different risk factors and may be attri-
butable to surgical technique rather than depressed
immune function. This result may explain why in our
study, fistulas were more frequent in one of the groups
with enriched diet (Group I). Fistulas, do not seem to
relate exclusively to infectious processes, and thus to
immunosuppression. Indeed, technical problems and
nutritional status might play an equally important role,
even independent of the immune status, and therefore
we might have overestimated the positive effect of
immunonutrition35. 
Based on these results, those planning future studies
face challenges. There is little evidence from the rando-
mised controlled trials reviewed here to guide the
choice of intervention, patient groups or the value of
preoperative supplementation. Clinically important
end-points such as fistula formation, wound infection
and pneumonia should be addressed. Any reduction in
length of hospital stay needs to be explained. A suitable
powered clinical trial is required before firm recom-
mendations can be made on the use of immunonutrition
in head and neck cancer patients postoperatively.
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